Sumatriptan monoamine oxidase inhibitors

Some of the triptans are metabolized by monoamine oxidase and they should not be used with monoamine oxidase inhibitors. This includes almotriptan (34), rizatriptan (35), sumatriptan (36), and zolmitriptan (28). The effect of moclobemide on the pharmacokinetics of almotriptan was less than with other triptans (34). 

Sumatriptan should be avoided by patients taking selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, moclobemide, St John s wort... 

The triptans are contraindicated in patients who have a history of ischemic or vasospastic CAD, cerebrovascular or peripheral vascular disease, or other significant cardiovascular diseases. Because triptans may cause an acute, usually small, increase in blood pressure (BP), they also are contraindicated in patients with uncontrolled hypertension. Naratriptan is contraindicated in patients with severe renal or hepatic impairment. Rizatriptan should be used with caution in patients with renal or hepatic disease but is not contraindicated in such patients. Sumatriptan, rizatriptan, and zolmitriptan are contraindicated in patients who are taking monoamine oxidase inhibitors. 

Glaxo Pharmaceuticals UK Limited. A study to determine whedier the pharmacokinetics, safety or tolerability of subcutaneously administered sumatriptan (6 mg) are altered by interaction with concurrent oral monoamine oxidase inhibitors. Data on file (Protocol C92-050),... 

Fox AW. Subcutaneous sumatriptan pharmacokinetics delimiting the monoamine oxidase inhibitor effect. Headache 2010 50 (2) 249-55. 

---